Company Filing History:
4 out of 260 
4 out of 7 Years Active: 2015-2019
Title: Innovator Jong Mun Son: Advancements in Therapy for Hunter Syndrome
Introduction
Jong Mun Son, a prolific inventor based in Yongin-si, South Korea, has made significant contributions to the field of pharmaceutical innovations. With a portfolio of four patents, he has focused on developing compositions that improve treatment options for rare diseases, particularly Hunter Syndrome.
Latest Patents
Among Jong Mun Son's latest patents is a groundbreaking composition and formulation that comprises recombinant human iduronate-2-sulfatase (IDS). This innovative approach involves a method for producing purified recombinant IDS, which is distinguished by its glycosylation pattern and formylglycine content, setting it apart from the existing treatment, ELAPRASE®. The new composition not only showcases superior pharmaceutical efficacy but also demonstrates improved safety profiles compared to conventional therapies, thereby providing a promising avenue for patients suffering from Hunter Syndrome.
Career Highlights
Jong Mun Son has held key positions in several esteemed organizations throughout his career. Notably, he has worked at The Green Cross Corporation and Medigenebio Corporation, where he applied his expertise in biopharmaceuticals to develop therapeutic solutions that address significant medical needs.
Collaborations
Throughout his career, Jong Mun Son has collaborated with talented individuals in the industry. Notable coworkers include Thong-Gyu Jin and Yo Kyung Chung, both of whom have contributed to the rich tapestry of research and development in the biopharmaceutical domain, assisting in realizing innovative therapies.
Conclusion
Jong Mun Son stands out as a dedicated inventor whose work is a testament to the potential of innovative therapies in treating rare diseases. His commitment to advancing pharmaceutical efficacy serves as an inspiration to many in the field, and his patented inventions continue to pave the way for improved treatment methods for conditions like Hunter Syndrome. As the landscape of biopharmaceuticals evolves, innovators like Son play an essential role in fostering advancements that hold the promise of hope for patients worldwide.